Enveda Therapeutics obtained FDA IND clearance and launched a Phase I trial for ENV‑6946, a first‑in‑class oral small molecule for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The initiation moves Enveda from discovery to clinical testing for a novel oral IBD candidate and reflects ongoing industry interest in small‑molecule immunomodulators. Company statements describe trial design and the therapeutic hypothesis behind the candidate.